Anvisa will give priority for registration of semaglutado and liraglutide

News Healthcare & Pharma Reports

Date: 25th Aug, 2025 Source: National Health Surveillance Agency (Anvisa) Country: Brazil Original Source

Brief

"On 25/08/2025, the National Health Surveillance Agency (Anvisa) issued an update regarding Anvisa will give priority for registration of semaglutado and liraglutide. The measure aims to ensure the supply of these medications in the Brazilian market, considering instability in their offer, as identified by Anvisa's surveillance area."

This content is restricted.

Highlights content goes here...

This content is restricted.

National Health Surveillance Agency (Anvisa)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

Anvisa will give priority for registration of semaglutado and liraglutide

Brief

National Health Surveillance Agency (Anvisa)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

Anvisa will give priority for registration of semaglutado and liraglutide

Brief

National Health Surveillance Agency (Anvisa)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.